Viralytics Looks To Combos To Ride Immuno-Oncology Wave
This article was originally published in PharmAsia News
Australian oncology venture Viralytics is on something of a roll, announcing additional positive Phase II data for its lead drug Cavatak and progress with new plans to assess the oncolytic virus in combination with immune checkpoint inhibitors following promising early results.
You may also be interested in...
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.